ArticleBMC cancer2025
Anti-PD-1 therapy achieves favorable outcome in gastric cancer combined with chronic hepatitis B.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- In vivo effect of anti-PD-1 on HIV-specific CD8+T-cells in men with HIV.Nature communications · 2026Article
- An overview of hepatitis B virus in gastric carcinogenesis: from clinical association to molecular mechanisms.Infectious agents and cancer · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate the efficacy and safety of immune checkpoint inhibitors in the treatment of gastric cancer patients with different hepatitis B virus (HBV) infection statuses. PATIENTS AND
methodsThe clinical data of 89 gastric cancer patients treated at our centre were retrospectively analysed. The patients were divided into chronic hepatitis B (CHB)-infected patients (13 patients), resolved hepatitis B (RHB)-infected patients (49 patients), and HBV-uninfected (HBV-) patients (27 patients) according to their HBV infection status. The efficacy and safety of antitumour treatment in patients in the three groups were analysed.
resultsDuring anti-programmed death (ligand) 1 (PD-(L)1) therapy, no significant differences in the overall response rate (69.2% vs. 53.1% vs. 51.9%; P = 0.536) or disease control rate (92.3% vs. 79.6% vs. 81.5%; P = 0.567) were observed among the three groups. Progression-free survival benefited more from anti-PD-(L)1 antibody therapy in CHB patients than in HBV- patients (Not reached vs. 7 months; P = 0.024; hazard ratio (HR) = 0.38(95%CI 0.17-0.88)) and RHB patients (Not reached vs. 6 months; P = 0.001; HR = 0.34(95%CI 0.17-0.65)). Overall survival was also better in CHB patients than in HBV- patients (Not reached vs. 15 months; P = 0.014; HR = 0.31(95%CI 0.12-0.79)) and RHB patients (Not reached vs. 16 months; P = 0.005; HR = 0.32(95%CI 0.14-0.71)).
conclusionAnti-PD-(L)1 immunotherapy may be safe and effective in gastric cancer patients with HBV infection. CHB patients are more likely to have lasting benefits than are HBV- patients and RHB patients. This may be attributed to alterations in the immune microenvironment in patients, and future studies should further explore the relevant mechanisms involved. CHB patients may have a more inflamed immune microenvironment, leading to enhanced ICI efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.